tetano
Editor, Senior Moderator
J Infect Dis
. 2023 Nov 10:jiad497.
doi: 10.1093/infdis/jiad497. Online ahead of print. Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status
Shuyi Zhong[SUP] 1 [/SUP], Tiffany W Y Ng[SUP] 1 [/SUP], Danuta M Skowronski[SUP] 2 3 [/SUP], A Danielle Iuliano[SUP] 4 [/SUP], Nancy H L Leung[SUP] 1 5 [/SUP], Ranawaka A P M Perera[SUP] 1 [/SUP], Faith Ho[SUP] 1 [/SUP], Vicky J Fang[SUP] 1 [/SUP], Yat Hung Tam[SUP] 1 [/SUP], Dennis K M Ip[SUP] 1 [/SUP], Fiona G Havers[SUP] 6 [/SUP], Alicia M Fry[SUP] 4 [/SUP], Eduardo Aziz-Baumgartner[SUP] 4 [/SUP], Ian G Barr[SUP] 7 8 [/SUP], Malik Peiris[SUP] 1 9 [/SUP], Mark G Thompson[SUP] 4 [/SUP], Benjamin J Cowling[SUP] 1 5 [/SUP]
Affiliations
Background: Annual influenza vaccination is recommended for older adults but repeated vaccination with standard-dose influenza vaccine has been linked to reduced immunogenicity and effectiveness, especially against A(H3N2) viruses.
Methods: Community-dwelling Hong Kong adults aged 65-82 years were randomly allocated to receive 2017/18 standard-dose quadrivalent, MF59-adjuvanted trivalent, high-dose trivalent, and recombinant-HA quadrivalent vaccination. Antibody response to unchanged A(H3N2) vaccine antigen was compared among participants with and without self-reported prior year (2016/17) standard-dose vaccination.
Results: Mean fold rise (MFR) in antibody titers from Day 0 to Day 30 by hemagglutination inhibition and virus microneutralization assays were lower among 2017/18 standard-dose and enhanced vaccine recipients with (range, 1.7-3.0) vs. without (range, 4.3-14.3) prior 2016/17 vaccination. MFR was significantly reduced by about one half to four fifths for previously vaccinated recipients of standard-dose and all three enhanced vaccines (β range, 0.21-0.48). Among prior-year vaccinated older adults, enhanced vaccines induced higher 1.43 to 2.39-fold geometric mean titers and 1.28 to 1.74-fold MFR vs. standard-dose vaccine by microneutralization assay.
Conclusions: In the context of unchanged A(H3N2) vaccine strain, prior-year vaccination was associated with reduced antibody response among both standard-dose and enhanced influenza vaccine recipients. Enhanced vaccines improved antibody response among older adults with prior-year standard-dose vaccination.
Keywords: antibody response; influenza vaccine; older adults; repeated vaccination.
. 2023 Nov 10:jiad497.
doi: 10.1093/infdis/jiad497. Online ahead of print. Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status
Shuyi Zhong[SUP] 1 [/SUP], Tiffany W Y Ng[SUP] 1 [/SUP], Danuta M Skowronski[SUP] 2 3 [/SUP], A Danielle Iuliano[SUP] 4 [/SUP], Nancy H L Leung[SUP] 1 5 [/SUP], Ranawaka A P M Perera[SUP] 1 [/SUP], Faith Ho[SUP] 1 [/SUP], Vicky J Fang[SUP] 1 [/SUP], Yat Hung Tam[SUP] 1 [/SUP], Dennis K M Ip[SUP] 1 [/SUP], Fiona G Havers[SUP] 6 [/SUP], Alicia M Fry[SUP] 4 [/SUP], Eduardo Aziz-Baumgartner[SUP] 4 [/SUP], Ian G Barr[SUP] 7 8 [/SUP], Malik Peiris[SUP] 1 9 [/SUP], Mark G Thompson[SUP] 4 [/SUP], Benjamin J Cowling[SUP] 1 5 [/SUP]
Affiliations
- PMID: 37950884
- DOI: 10.1093/infdis/jiad497
Background: Annual influenza vaccination is recommended for older adults but repeated vaccination with standard-dose influenza vaccine has been linked to reduced immunogenicity and effectiveness, especially against A(H3N2) viruses.
Methods: Community-dwelling Hong Kong adults aged 65-82 years were randomly allocated to receive 2017/18 standard-dose quadrivalent, MF59-adjuvanted trivalent, high-dose trivalent, and recombinant-HA quadrivalent vaccination. Antibody response to unchanged A(H3N2) vaccine antigen was compared among participants with and without self-reported prior year (2016/17) standard-dose vaccination.
Results: Mean fold rise (MFR) in antibody titers from Day 0 to Day 30 by hemagglutination inhibition and virus microneutralization assays were lower among 2017/18 standard-dose and enhanced vaccine recipients with (range, 1.7-3.0) vs. without (range, 4.3-14.3) prior 2016/17 vaccination. MFR was significantly reduced by about one half to four fifths for previously vaccinated recipients of standard-dose and all three enhanced vaccines (β range, 0.21-0.48). Among prior-year vaccinated older adults, enhanced vaccines induced higher 1.43 to 2.39-fold geometric mean titers and 1.28 to 1.74-fold MFR vs. standard-dose vaccine by microneutralization assay.
Conclusions: In the context of unchanged A(H3N2) vaccine strain, prior-year vaccination was associated with reduced antibody response among both standard-dose and enhanced influenza vaccine recipients. Enhanced vaccines improved antibody response among older adults with prior-year standard-dose vaccination.
Keywords: antibody response; influenza vaccine; older adults; repeated vaccination.